杂合致病性COL4A3和COL4A4变异(常染色体显性Alport综合征)常见,且通常不与终末期肾衰竭、听力损失或眼部异常相关
本文讨论杂合致病性COL4A3或COL4A4变异(常染色体显性Alport综合征)的临床意义。基于人群等位基因频率与无选择队列的推算提示,该类变异在正常人群中比COL4A5变异常见20倍,而因之发生终末期肾衰竭的风险比X连锁Alport综合征低20倍,60岁时终末期肾衰竭外显率不足3%,听力损失和眼部异常不常见。
要点
- 杂合致病性COL4A3或COL4A4变异在正常人群中比COL4A5变异常见20倍。
- 常染色体显性Alport综合征发生终末期肾衰竭的风险比X连锁Alport综合征低20倍。
- 60岁时杂合致病性COL4A3或COL4A4变异者终末期肾衰竭外显率不足3%,听力损失和眼部异常不常见。
核心结论
- 常染色体显性Alport综合征由杂合致病性COL4A3或COL4A4变异引起,在正常人群中常见,发生终末期肾衰竭的风险远低于X连锁Alport综合征,且通常不伴听力损失或眼部异常。
研究设计与样本
- 本文为针对杂合致病性COL4A3或COL4A4变异(常染色体显性Alport综合征)的临床意义进行论述的综述,引用医院来源患者研究和无选择队列的等位基因频率数据。
主要发现
- 既往研究提示杂合致病性COL4A3或COL4A4变异者终末期肾衰竭发生率为14%至30%,但听力损失和眼部缺陷不常见或甚至不出现。
- 多个无选择终末期肾衰竭队列发现杂合致病性COL4A3和COL4A4变异的发生频率与COL4A5变异大致相当。
- 正常人群中杂合致病性COL4A3和COL4A4变异的存在频率比COL4A5变异高20倍。
- 据此推算,常染色体显性Alport综合征并发终末期肾衰竭的频率比X连锁Alport综合征低20倍,60岁时杂合致病性COL4A3或COL4A4变异者终末期肾衰竭外显率不足3%。
- 因杂合致病性COL4A3或COL4A4变异转诊至医院者,发生肾功能受损的可能性仍高于未确诊而留在家中的个体。
关键数值与推荐
- 杂合致病性COL4A3或COL4A4变异者终末期肾衰竭发生率14%至30%(引自既往医院来源研究)。
- 正常人群中杂合致病性COL4A3和COL4A4变异频率为COL4A5变异的20倍。
- 常染色体显性Alport综合征并发终末期肾衰竭频率为X连锁Alport综合征的1/20。
- 60岁时杂合致病性COL4A3或COL4A4变异者终末期肾衰竭外显率不足3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 所有引用的杂合致病性COL4A3或COL4A4变异与肾衰竭研究均来自医院来源患者,因而偏向于更严重的疾病。
- 杂合致病性COL4A3或COL4A4变异者中终末期肾衰竭的风险仍存在不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The term "autosomal dominant (AD) Alport syndrome" is often used to describe the condition associated with heterozygous pathogenic COL4A3 or COL4A4 variants and has largely replaced "thin basement membrane nephropathy (TBMN)." AD Alport syndrome implies that affected individuals develop end-stage kidney failure (ESKF) as well as the typical Alport hearing loss and ocular abnormalities, but these features have been considered rare with TBMN. Recent studies suggest that ESKF occurs in 14% to 30% of those with heterozygous pathogenic COL4A3 or COL4A4 variants but confirm that the hearing loss and ocular defects occur uncommonly if at all. Uncertainty over the risk of ESKF has persisted. However all the cited studies of heterozygous pathogenic COL4A3 or COL4A4 variants and kidney failure are from hospital-based patients and thus biased toward more severe disease. Multiple unselected cohorts with ESKF have found heterozygous pathogenic variants in COL4A3 and COL4A4 occur about as often as COL4A5 variants, which suggests that AD Alport syndrome causes ESKF as often as X-linked (XL) disease. In the normal population, heterozygous pathogenic COL4A3 and COL4A4 variants are present 20 times more often than COL4A5 variants. Therefore, AD Alport syndrome is complicated by ESKF 20 times less often than XL disease and occurs in fewer than 3% of those with pathogenic COL4A3 or COL4A4 variants by the age of 60. Nevertheless, individuals with heterozygous pathogenic COL4A3 or COL4A4 variants referred to a hospital are still more likely to develop impaired kidney function than those who remain at home undiagnosed.
引用
- Savige J. Heterozygous Pathogenic COL4A3 and COL4A4 Variants (Autosomal Dominant Alport Syndrome) Are Common, and Not Typically Associated With End-Stage Kidney Failure, Hearing Loss, or Ocular Abnormalities. Kidney Int Rep. 2022. PMID: 36090501. doi:10.1016/j.ekir.2022.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。